MedTrace Logo

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

NCT02531360 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-12-16

No results posted yet for this study

Summary

The overall goal of this imaging trial is to characterize \[18F\]MNI-815, a PET radioligand for imaging Tau.

Conditions

  • Alzheimer's Disease (AD)
  • Progressive Supranuclear Palsy (PSP)
  • Cortical Basal Syndrome (CBS)
  • Frontal Temporal Dementia (FTD)

Interventions

DRUG

[18F]MNI-815 (MNI-815)

All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.

Sponsors & Collaborators

  • Life Molecular Imaging SA

    collaborator INDUSTRY

  • Molecular NeuroImaging

    lead OTHER

Principal Investigators

  • Danna Jennings, MD · Molecular NeuroImaging, LLC

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-07-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02531360 on ClinicalTrials.gov